BMI was the main risk factors to influence the NAFLD regression or progression in our study. The results showed that BMI had the most effect on the regression and progression of NAFLD; the reduction in BMI increased the regression of NAFLD and vice versa. However, increasing BMI had a bit more effect on increasing the probability of progression of NAFLD than reduction of BMI in increasing relative risk of its regression. Although NAFLD and its more severe form, NASH, might develop in non-obese patients, the dominant portion of these diseases occurs in obese or overweight individuals (
14). The BMI, WC, and weight-to-height ratio were observed to be associated with NAFLD, with BMI being a better index for diagnosing NAFLD (
2). Closely associated with NAFLD development and its progression, obesity is a pro-inflammatory condition resulting in insulin resistance (
25). It was suggested that, weight reduction, with its clear dose-response association, is the most established treatment for both NAFLD and NASH. In other word the effect of weight loss on histological improvement of liver was found to be dependent on the weight reduction degree, regardless of the method employed to reach it (
3). Romero-Gomez, et al. had also showed that weight loss had been further underlined in NASH patients, where weight loss > 7% was related to a clinically meaningful regression of disease status and weight reduction of ≥ 10% was able to ameliorate fibrosis by at least one stage (
3) and resulted in improvement of liver enzymes and histology (
26). Furthermore, a modest 3 - 5 kg weight gain, regardless of baseline BMI, predicted the development of NAFLD (
27). In another study on NASH patients, those with 10% (or more) loss of the total body weight had observably higher rates of fibrosis regression (63% vs.9%) (
28).
In western countries, visceral obesity was reported to be associated with the pathogenesis of NAFLD, compared with the overall obesity (
29). Accordingly, WC was a well-known surrogate marker of abdominal fat accumulation. However, similar to Hu et al. study that was conducted in East Asia (
2), we found that BMI was superior to WC and was a better index of NAFLD status. Fracanzani et al. showed that there was a significant correlation between hepatic steatosis and visceral adiposity, yet failed to show that WC and NASH were correlated at multivariate analysis (
30). They indeed proposed that with the appearance of NASH, visceral fat is no longer a significant determinant of the degree of liver damage.
Using ultrasonography was the limitation of our study. In NAFLD, the primary disease of interest is NASH as this NAFLD phenotype carries the risk of hepatic fibrosis and cirrhosis- Ultrasonography findings are unable to differentiate whether nonalcoholic fatty liver or NASH is present. Histopathological findings are excellent benchmarks for the diagnosis of NAFLD; and liver elastography also was a costly method which were not easily accessible to use in our cohort study. Furthermore, Medication adherence was self-reported which was a limitation in our study. As a recommendation, revealing the effect of treatments in participants with decreased BMI, and its effect on regression of NAFLD should be considered in the future studies. We also suggest to compare groups with fixed severity of NAFLD at the beginning and end of the cohort study with other groups in the next researches. According to evidence of obesity and development of NAFLD in children, follow-up cohort on this age group is suggested.